Ikena Oncology, Inc.IKNANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P43
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-6.12%
2024-49.06%
2023-7.26%
202236.54%
20215.04%
202079.83%
2019-35.33%
20180.00%